Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness: During or After Chemotherapy
Published in: Jacc: cardiooncology
Access to document
10.1016/j.jaccao.2022.07.006
document
BACKGROUND: Despite the widely acknowledged benefit of exercise for patients with cancer, little evidence on the optimal timing of exercise on adverse effects of cancer treatment is available. OBJECTIVES: The aim of this study was to determine whether an exercise intervention initiated during chemotherapy is superior to an intervention initiated after chemotherapy for improving long-term cardiorespiratory fitness (peak oxygen uptake [VO 2peak]). METHODS: In this prospective, randomized clinical trial, patients scheduled to receive curative chemotherapy were randomized to a 24-week exercise intervention, initiated either during chemotherapy (group A)...
Gabriela G.F. van der Schoot, Harm L. Ormel, Nico-Derk L. Westerink, Anne M. May, Sjoerd G. Elias, Yoran M. Hummel, Joop D. Lefrandt, Peter van der Meer, Joost P. van Melle, Boelo J. Poppema, Joyce M.A. Stel, Annette W.G. van der Velden, Aline H. Vrieling, Johan B. Wempe, Marcel G. ten Wolde, Marcel Nijland, Elisabeth G.E. de Vries, Jourik A. Gietema, Annemiek M.E. Walenkamp
Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma: a population-based analysis
Published in: European Journal of Cancer
Access to document
10.1016/j.ejca.2022.09.008
document
Background: Patients with angioimmunoblastic T-cell lymphoma (AITL) are treated with cyclophosphamide, doxorubicin, vincristine and prednisone with or without etoposide (CHO(E)P). In the majority of cases, Epstein–Barr virus (EBV)-positive B-cells are present in the tumour. There is paucity of research examining the effect of rituximab when added to CHO(E)P. In this nationwide, population-based study, we analysed the impact of rituximab on overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) of patients with AITL. Methods: Patients with AITL diagnosed between 2014 and 2020 treated with ≥one cycle...
Frederik O. Meeuwes, Mirian Brink, Marjolein W.M. van der Poel, Marie José Kersten, Mariëlle Wondergem, Pim G.N.J. Mutsaers, Lara Böhmer, Sherida Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M. Jansen, Arjan Diepstra, Tjeerd J.F. Snijders, Wouter J. Plattel, Gerwin A. Huls, Joost S.P. Vermaat, Marcel Nijland
IBCL-460 Subcutaneous Epcoritamab With Rituximab + Lenalidomide (R2) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Update from Phase 1/2 Trial
Published in: Clinical Lymphoma, Myeloma and Leukemia
Access to document
10.1016/S2152-2650(22)01565-8
document
Context: R/R FL is associated with a poor prognosis and remains incurable; thus, better treatment options are needed. Epcoritamab is a subcutaneously administered CD3xCD20 bispecific antibody that has shown substantial antitumor activity in R/R FL. Objective: Evaluate safety and efficacy of epcoritamab with R2 in patients with R/R FL in arm 2 of a phase 1/2 open-label trial (EPCORE NHL-2; NCT04663347). Patients: Adults with R/R CD20+ FL were included. As of December 1, 2021, 30 patients (median age, 68 y) had enrolled. Interventions: Patients received subcutaneous epcoritamab (QW,...
Lorenzo Falchi, Sirpa Leppä, Björn E. Wahlin, Marcel Nijland, Jacob Haaber Christensen, Sven de Vos, Harald Holte, Kim M. Linton, Aqeel Abbas, Liwei Wang, Minh Dinh, Brian Elliott, David Belada
R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma
Published in: Blood cancer journal
Access to document
10.1038/s41408-022-00723-4
document
Diana Al-Sarayfi, Frederik O. Meeuwes, Mujde Durmaz, Djamila E. Issa, Rolf E. Brouwer, Aart Beeker, Anna van Rhenen, Pim G. N. J. Mutsaers, Lara H. Bohmer, Marjolein W. M. van der Poel, Liane te Boome, Tom van Meerten, Martine E. D. Chamuleau, Josee M. Zijlstra, Mirian Brink, Marcel Nijland
Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study
Published in: Blood
Access to document
10.1182/blood.2021015114
document
Patients aged <65 years with peripheral T-cell lymphoma (PTCL) are treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Although the addition of etoposide (CHOEP) and consolidation with autologous stem cell transplantation (ASCT) are preferred in some countries, randomized trials are lacking. This nationwide population-based study assessed the impact of etoposide and ASCT on overall survival (OS) among patients aged 18 to 64 years with stage II to IV anaplastic large-cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL), or PTCL not otherwise specified (NOS) diagnosed between 1989 and 2018 using...
Mirian Brink, Frederik O. Meeuwes, Marjolein W.M. van der Poel, Marie José Kersten, Mariëlle Wondergem, Pim G.N.J. Mutsaers, Lara H. Böhmer, F. J.Sherida H. Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M. Jansen, Wouter Plattel, Gerwin A. Huls, Joost S.P. Vermaat, Marcel Nijland